Medtronic Invests $90M in Anteris Technologies for TAVR Development
Medtronic (NYSE: MDT) is making a bold move in the transcatheter aortic valve replacement (TAVR) market. The company plans to invest $90 million in Anteris Technologies Global, a firm specializing in innovative TAVR devices. However, this investment hinges on a key condition: Anteris must secure a $200 million initial public offering (IPO).
Once the IPO is complete, Medtronic will purchase shares at the same price offered to the public. The deal ensures Medtronic acquires at least 16% of Anteris’ shares, with a maximum cap of 19.99%.
At the heart of this partnership is Anteris’ DurAVR device. This TAVR system features a biomimetic valve designed to mimic the function of a healthy human aortic valve. The valve is crafted from Anteris’ proprietary ADAPT tissue, which incorporates FDA-cleared anti-calcification technology. This innovation aims to improve durability and performance.
Currently, Anteris is conducting a clinical trial in Denmark to evaluate the safety and efficacy of the DurAVR valve. The funds raised from the IPO will support this study, aid in patient recruitment, and expand the company’s manufacturing capabilities.
The TAVR market has seen significant growth in recent years. Patients and physicians are increasingly drawn to its minimally invasive approach. Medtronic, a major player in this space, already has its own TAVR system—the Evolut. Recent data from the Evolut Low Risk Trial showed promising five-year outcomes. In low-risk patients with severe aortic stenosis, TAVR with Evolut demonstrated comparable results to surgery. Notably, TAVR patients had lower cardiovascular mortality rates (7.2%) compared to surgery (9.3%) over five years.
This strategic investment underscores Medtronic’s commitment to advancing TAVR technology. By partnering with Anteris, the company aims to strengthen its position in this rapidly evolving market.
To learn more about Medtronic’s financial outlook, please visit www.investorrelations.medtronic.com.
